| Dr Adriel J Malave, MD | |
|
1400 Jackson St, Denver, CO 80206 | |
| (303) 388-4461 | |
| (303) 398-1211 |
| Full Name | Dr Adriel J Malave |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 19 Years |
| Location | 1400 Jackson St, Denver, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457535403 | NPI | - | NPPES |
| 281981501 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | N9257 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| National Jewish Health | Denver, CO | Hospital |
| Saint Joseph Hospital | Denver, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| National Jewish Health | 4587577028 | 220 |
News Archive
Agilent Technologies Inc. today announced it has completed the acquisition of the BioSystem Development business. BioSystem Development is a privately held company that develops and manufactures the AssayMAP Microchromatography platform to meet the analytical needs of the life sciences industry.
An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
A small clinical trial of patients with multiple sclerosis (MS) who did not respond to interferon alone found that adding the human antibody daclizumab improved patient outcome. Patients who received the combined therapy had a 78 percent reduction in new brain lesions and a 70 percent reduction in total lesions, along with other significant clinical improvements.
› Verified 8 days ago
| Entity Name | National Jewish Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326015777 PECOS PAC ID: 4587577028 Enrollment ID: O20031110000757 |
News Archive
Agilent Technologies Inc. today announced it has completed the acquisition of the BioSystem Development business. BioSystem Development is a privately held company that develops and manufactures the AssayMAP Microchromatography platform to meet the analytical needs of the life sciences industry.
An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
A small clinical trial of patients with multiple sclerosis (MS) who did not respond to interferon alone found that adding the human antibody daclizumab improved patient outcome. Patients who received the combined therapy had a 78 percent reduction in new brain lesions and a 70 percent reduction in total lesions, along with other significant clinical improvements.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adriel J Malave, MD 1400 Jackson St, Denver, CO 80206 Ph: (303) 388-4461 | Dr Adriel J Malave, MD 1400 Jackson St, Denver, CO 80206 Ph: (303) 388-4461 |
News Archive
Agilent Technologies Inc. today announced it has completed the acquisition of the BioSystem Development business. BioSystem Development is a privately held company that develops and manufactures the AssayMAP Microchromatography platform to meet the analytical needs of the life sciences industry.
An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
A small clinical trial of patients with multiple sclerosis (MS) who did not respond to interferon alone found that adding the human antibody daclizumab improved patient outcome. Patients who received the combined therapy had a 78 percent reduction in new brain lesions and a 70 percent reduction in total lesions, along with other significant clinical improvements.
› Verified 8 days ago
Katrina Wagoner-hursh, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1835 Franklin St, Denver, CO 80218 Phone: 303-338-4545 | |
Emily Martin Jones, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8111 E Lowry Blvd, Denver, CO 80230 Phone: 720-848-0000 | |
Dr. Jesus Heliodoro Hermosillo Rodriguez, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Margaret Hay, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1601 E 19th Ave Ste 3100, Denver, CO 80218 Phone: 303-863-0300 Fax: 303-863-7014 | |
Dr. Alan W Burgess, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1601 E 19th Ave Ste 6000, Denver, CO 80218 Phone: 303-861-7001 Fax: 303-861-8624 | |
Dr. Sahibzada Mohsin Shah, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 777 Bannock St, Denver, CO 80204 Phone: 303-436-6000 | |
Shyam M Parkhie, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 130 Rampart Way, 300b, Denver, CO 80230 Phone: 720-343-1562 Fax: 720-343-1563 |